Microbiome Impact on the Susceptibility and Severity to Cryptosporidium Infection
Microbiome Impact on the Susceptibility and Severity to Cryptosporidium Infection
批准号:
10338198
负责人:
JAN R MEAD
金额:
$19.56万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
已结题
起止时间:
2021-02-02 至 2023-01-31
关键词:
AdultAffectAmino AcidsAntibioticsBacteriaC57BL/6 MouseCell secretionCellsChildChildhoodChronicCryptosporidiosisCryptosporidiumCryptosporidium parvumDataDeveloping CountriesDiarrheaDiseaseDisease susceptibilityEnvironmentEpithelial CellsExploratory/Developmental GrantFDA approvedGerm-FreeGoalsGrowthGut MucosaHIVHost resistanceHumanImmune responseImmunocompetentImmunocompromised HostIndividualInfectionInterferonsInterventionIntestinesLeadLifeLinkLipidsMalnutritionMeasuresMetabolicMissionMusNatureOrganismParasitesParasitic infectionPatternPharmaceutical PreparationsPhenotypePlayPredispositionPreventiveProbioticsResearchResistanceResistance profileResistance to infectionRoleRotavirusSeveritiesSeverity of illnessSmall IntestinesStructureT cell responseT-Cell ActivationT-LymphocyteTestingTherapeuticTransplant RecipientsTransplantationUnited States National Institutes of HealthVaccinesVolatile Fatty AcidsVulnerable Populationsbacterial communitybacterial resistancebasecell growthcolonization resistancecytokinediarrheal diseasedrug repurposingfecal transplantationgut microbiomegut microbiotaimmunological statusinfection riskmetabolic profilemicrobiomemicrobiome alterationmicrobiotamicrobiota profilesmouse modelnovelpathogenresponsetreatment strategy
中文摘要
隐孢子虫。是感染小鼠上皮细胞的机会性原生动物寄生虫
肠道,导致人类腹泻疾病。在免疫缺陷个体中,这种疾病可能会很严重,
慢性的,甚至是致命的。在成人和儿童中,这种疾病的范围从无症状到严重。
这些易感性和疾病严重程度的差异被认为部分是由于免疫学上的原因。
宿主状况、营养不良或以前的接触情况。但有一个重要因素的研究有限,那就是
微生物区系在寄主抗性中的作用。虽然微生物区系的差异与
敏感性,目前还不清楚哪些细菌微生物区系在耐药性中起重要作用,哪些可能
使个人预先准备好感染或更严重的疾病。人们也不知道它是如何改变的
微生物区系改变肠道中的新陈代谢及其对免疫反应的影响
主人的名字。我们的长期目标是了解潜在的肠道环境及其可能发生的原因
与感染的易感性和严重程度有关。我们的目标是确定
微生物区系影响对感染的抵抗力和易感性,并确定总体模式或概况
可以辨认出来。此外,我们计划确定以下变化之间是否存在关联
细菌代谢物和感染水平。这一提议的中心假设是,
微生物群改变了对微小弧菌感染易感性和宿主免疫反应,从而允许
更大的有机体扩张。我们将通过用不同的抗生素治疗小鼠来检验这一假设
以及一种已知可以改变肠道菌群并检查这些变化如何影响的改变用途的药物
易感性、感染水平和宿主免疫反应,特别是T细胞和细胞因子的激活
在当地环境中做出反应。这一假设的理论基础是基于我们的初步数据
这表明,用某些抗生素处理的小鼠的微生物群发生了显著的变化
与车辆对照组小鼠相比,这导致了更高的敏感性。此外,新陈代谢
将进行分析,以确定短链脂肪酸水平、氨基酸和脂质的变化。
我们将把代谢产物的不同与易感性和生长联系起来。这些变化可能随后
改变免疫反应和微生物区系相关代谢产物,导致局部T细胞的调节
细胞和关键细胞因子的分泌,如干扰素-。这些发现将具有重要意义,因为它将
有助于促进对隐孢子虫病扩大潜在机制的理解
脆弱性增加的条件。此外,通过识别符合以下条件的个体的微生物区系特征
感染风险更大(例如,免疫缺陷个人、移植受者和幼儿);
可以采取干预措施来支持或改变微生物区系,使其具有更强的抗药性。
英文摘要
Cryptosporidium spp. are opportunistic protozoan parasites that infect epithelial cells of the small
intestine, causing diarrheal illness in humans. In immunodeficient individuals, the disease can be severe,
chronic and even fatal. In both adults and children, the disease can range from asymptomatic to severe.
These differences in susceptibility and disease severity are known to be due in part to immunological
status of the host, malnutrition, or prior exposure. But one important factor that has had limited study, is
the role microbiota plays in host resistance. While differences in microbiota have been linked to
susceptibility, it is not clear which bacterial microbiota profiles are important in resistance and which might
pre-dispose individuals to infections or to more severe disease. It is also not understood how altered
microbiota changes the metabolic profile in the intestinal tract and how this impacts the immune response
of the host. Our long-term goal is to understand the underlying gut environment and how that may be
related to susceptibility and severity of infection. Our objective is to determine how differences in
microbiota affect resistance and susceptibility to infections and to determine if overall patterns or profiles
can be identified. Additionally, we plan to determine if there is an association between changes in
bacterial metabolites and infection levels. The central hypothesis in this proposal is that differences in
the microbiota alter susceptibility and host immune response to C. parvum infection which allow for
greater expansion of the organism. We will test this hypothesis by treating mice with different antibiotics
and a repurposed drug known to alter the intestinal flora and examine how these changes affect
susceptibility, infection level, and host immune responses, particularly activation of T cells and cytokine
response in the local environment. The rationale for this hypothesis is based on the our preliminary data
that show that there are significant changes in the microbiome of mice treated with certain antibiotics
compared to vehicle control mice, which results in increased susceptibility. Additionally, metabolic
analyses will be performed to determine changes in short chain fatty acid levels, amino acids and lipids.
We will correlate difference in metabolites to susceptibility and growth. These changes may subsequently
alter the immune response and microbiota-associated metabolites that result in modulation of local T
cells and secretion of key cytokines, such as IFN-. These findings would be significant because it would
help advance the understanding of mechanisms underlying the expansion of cryptosporidiosis during
conditions of increased vulnerability. In addition, by identifying microbiota profiles in individuals that are
at greater risk of infection (e.g immunodeficient individuals, transplant recipients, and young children),
interventions could be administered to bolster or alter the microbiota to a more resistant profile.
期刊论文(2)
专著(0)
科研奖励(0)
会议论文
DOI:
10.3389/fpara.2023.1113950
发表时间:
2023-01-01
期刊:
Frontiers in parasitology
影响因子:
--
作者:
[Mead, Jan R]
通讯作者:
Mead, Jan R
DOI:
10.3390/microorganisms10091822
发表时间:
2022-09-11
期刊:
Microorganisms
影响因子:
4.5
作者:
[Keelaghan AP, Charania R, Mead JR]
通讯作者:
Mead JR
Microbiome Impact on the Susceptibility and Severity to Cryptosporidium Infection
-
批准号:10252399
-
项目类别:
-
资助金额:$23.43万
-
财政年份:2021
-
负责人:JAN R MEAD
-
依托单位:
Mucosal Immunity and the Role of TH1 Cytokines in a Model of Cryptosporidiosis
-
批准号:8391629
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2010
-
负责人:JAN R MEAD
-
依托单位:
Mucosal Immunity and the Role of TH1 Cytokines in a Model of Cryptosporidiosis
-
批准号:8597404
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2010
-
负责人:JAN R MEAD
-
依托单位:
Mucosal Immunity and the Role of TH1 Cytokines in a Model of Cryptosporidiosis
-
批准号:8198365
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2010
-
负责人:JAN R MEAD
-
依托单位:
Mucosal Immunity and the Role of TH1 Cytokines in a Model of Cryptosporidiosis
-
批准号:8045925
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2010
-
负责人:JAN R MEAD
-
依托单位:
IMMUNODOMINANT TARGETS OF CMI TO CRYPTOSPORIDIUM
-
批准号:6532705
-
项目类别:
-
资助金额:$18.0万
-
财政年份:1996
-
负责人:JAN R MEAD
-
依托单位:
IMMUNODOMINANT TARGETS OF CMI TO CRYPTOSPORIDIUM
-
批准号:7198162
-
项目类别:
-
资助金额:$21.42万
-
财政年份:1996
-
负责人:JAN R MEAD
-
依托单位:
IMMUNODOMINANT TARGETS OF CMI TO CRYPTOSPORIDIUM
-
批准号:7091583
-
项目类别:
-
资助金额:$22.06万
-
财政年份:1996
-
负责人:JAN R MEAD
-
依托单位:
IMMUNODOMINANT TARGETS OF CMI TO CRYPTOSPORIDIUM
-
批准号:7585748
-
项目类别:
-
资助金额:$21.01万
-
财政年份:1996
-
负责人:JAN R MEAD
-
依托单位:
IMMUNODOMINANT TARGETS OF CMI TO CRYPTOSPORIDIUM
-
批准号:2073113
-
项目类别:
-
资助金额:$16.15万
-
财政年份:1996
-
负责人:JAN R MEAD
-
依托单位:
IMMUNODOMINANT TARGETS OF CMI TO CRYPTOSPORIDIUM
-
批准号:6616756
-
项目类别:
-
资助金额:$19.2万
-
财政年份:1996
-
负责人:JAN R MEAD
-
依托单位:
IMMUNODOMINANT TARGETS OF CMI TO CRYPTOSPORIDIUM
-
批准号:7388945
-
项目类别:
-
资助金额:$21.01万
-
财政年份:1996
-
负责人:JAN R MEAD
-
依托单位:
IMMUNODOMINANT TARGETS OF CMI TO CRYPTOSPORIDIUM
-
批准号:2672387
-
项目类别:
-
资助金额:$17.47万
-
财政年份:1996
-
负责人:JAN R MEAD
-
依托单位:
IMMUNODOMINANT TARGETS OF CMI TO CRYPTOSPORIDIUM
-
批准号:6146774
-
项目类别:
-
资助金额:$19.2万
-
财政年份:1996
-
负责人:JAN R MEAD
-
依托单位:
IMMUNODOMINANT TARGETS OF CMI TO CRYPTOSPORIDIUM
-
批准号:6373417
-
项目类别:
-
资助金额:$19.2万
-
财政年份:1996
-
负责人:JAN R MEAD
-
依托单位:
IMMUNODOMINANT TARGETS OF CMI TO CRYPTOSPORIDIUM
-
批准号:2413695
-
项目类别:
-
资助金额:$16.8万
-
财政年份:1996
-
负责人:JAN R MEAD
-
依托单位:
IMMUNODOMINANT TARGETS OF CMI TO CRYPTOSPORIDIUM
-
批准号:6947026
-
项目类别:
-
资助金额:$19.2万
-
财政年份:1996
-
负责人:JAN R MEAD
-
依托单位:
DEVELOPMENT OF DRUGS FOR CRYPTOSPORIDIUM INFECTION
-
批准号:2295499
-
项目类别:
-
资助金额:$14.3万
-
财政年份:1992
-
负责人:JAN R MEAD
-
依托单位:
DEVELOPMENT OF DRUGS FOR CRYPTOSPORIDIUM INFECTION
-
批准号:2295491
-
项目类别:
-
资助金额:$0.0万
-
财政年份:1992
-
负责人:JAN R MEAD
-
依托单位:
DEVELOPMENT OF DRUGS FOR CRYPTOSPORIDIUM INFECTION
-
批准号:2295498
-
项目类别:
-
资助金额:$25.4万
-
财政年份:1992
-
负责人:JAN R MEAD
-
依托单位:
海外基金